Sandoz-backed study puts US 10-year saving from biosimilars at $54 billion

Biosimilars could cut healthcare spending in the USA by $54 billion over the next decade, says a study from the RAND Corporation, a non-profit institution that helps improve policy and decision-making through research and analysis.

The research was backed by Sandoz, the biosimilars and generics unit of Swiss pharma giant Novartis (NOVN: VX).

"There remains many important industry, regulatory and policy decisions to be made that will influence whether such savings are realized"